Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study

OBJECTIVE: The equivalence of the biosimilar HS016 to adalimumab (Humira) for the treatment of active ankylosing spondylitis (AS) patients has been previously validated. The aim was to compare the efficacy of HS016 and adalimumab in stratified subgroups at different time points using Health Assessme...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Jinmei, Li, Mengtao, He, Lan, Zhao, Dongbao, Wan, Weiguo, Liu, Yi, Xu, Jianhua, Xu, Jian, Liu, Huaxiang, Jiang, Lindi, Wu, Huaxiang, Zuo, Xiaoxia, Huang, Cibo, Liu, Xiumei, Li, Fen, Zhang, Zhiyi, Liu, Xiangyuan, Dong, Lingli, Li, Tianwang, Chen, Haiying, Li, Jingyang, He, Dongyi, Lu, Xin, Huang, Anbin, Tao, Yi, Wang, Yanyan, Zhang, Zhuoli, Wei, Wei, Li, Xiaofeng, Zeng, Xiaofeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873115/
https://www.ncbi.nlm.nih.gov/pubmed/34709497
http://dx.doi.org/10.1007/s10067-021-05943-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873115/
https://www.ncbi.nlm.nih.gov/pubmed/34709497
http://dx.doi.org/10.1007/s10067-021-05943-w

Ejemplares similares